Please login to the form below

Not currently logged in
Email:
Password:

Morphotek

This page shows the latest Morphotek news and features for those working in and with pharma, biotech and healthcare.

MaxCyte gets green light for solid tumour cell therapy

MaxCyte gets green light for solid tumour cell therapy

Mesothelin is expressed at elevated levels by a number of cancer types, including prostate and bile duct cancer, and  has also been targeted by antibody-based drugs such as Morphotek’s

Latest news

  • Christina Coughlin to leave Immunocore for Tmunity Christina Coughlin to leave Immunocore for Tmunity

    She went on to lead early development programmes at Novartis, including in checkpoint and PI3K inhibitors, and then leadership roles at Morphotek, Pfizer and Wyeth.

  • Late-stage ovarian cancer Late-stage ovarian cancer

    Menarini Biotech's abagovomab and Morphotek/ Eisai's farletuzumab have both had disappointing results in late-stage clinical trials.

  • Eisai's farletuzumab fails ovarian cancer trial Eisai's farletuzumab fails ovarian cancer trial

    Morphotek remains committed to research to understand the potential role of farletuzumab in ovarian and other types of cancer.". ... Eisai acquired Morphotek in 2007 in a $325m deal designed to bring in a portfolio of oncology drug candidates.

  • Eisai subsidiary in tie up for prostate cancer antibodies

    Eisai subsidiary Morphotek signs a R&D agreement with the National Cancer Institute for the development of therapeutic antibodies to a cancer-associated protein. ... Morphotek will apply its proprietary Morphodoma antibody technology to the development

  • Eisai acquires MGI Pharma for USD 3.9bn

    In 2006, Eisai bought four cancer drugs from Ligand Pharmaceuticals for a total of USD 205m, while in early 2007 the company spent USD 325m on the buy up of Morphotek.

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Deal Watch table for June 2014 Deal Watch table for June 2014

    68. Sorrento Therapeutics / Morphotek. Research and option agreement. To generate chemotherapeutic antibody drug conjugates (ADCs) (platform).

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Creative Medical Research

Specialising in medical device market research and participant recruitment human factors research, our approach is people-centric. We thrive on making...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics